초록 ▼

Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise ino

Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

대표청구항 ▼

1. A metal-organic framework (MOF) comprising: a) a photosensitizer; andb) a plurality of metal-containing secondary building units (SBUs) linked together via bridging ligands, wherein the SBUs are metal oxo clusters and wherein one or more of the SBUs comprise metal cations selected from cations of

1. A metal-organic framework (MOF) comprising: a) a photosensitizer; andb) a plurality of metal-containing secondary building units (SBUs) linked together via bridging ligands, wherein the SBUs are metal oxo clusters and wherein one or more of the SBUs comprise metal cations selected from cations of the group consisting of Hf, Ta, W, and Bi. 2. The MOF of claim 1, further comprising at least one of a polyoxometalate, a metallic nanoparticle, or a metal oxide nanoparticle located in cavities or channels in the MOF. 3. The MOF of claim 1, wherein each bridging ligand comprises an organic compound comprising multiple coordination sites, optionally wherein each bridging ligand comprises between 2 and 10 coordination sites. 4. The MOF of claim 1, wherein each bridging ligand is capable of binding to two or three SBUs. 5. The MOF of claim 1, wherein each bridging ligand comprises at least two groups wherein each of said two groups is individually selected from the group consisting of a carboxylate, an aromatic or non-aromatic nitrogen-containing group, a phenol, an acetylacetonate, a phosphonate, and a phosphate, optionally wherein said aromatic nitrogen-containing group is a pyridine group. 6. The MOF of claim 1, wherein at least one of the bridging ligands comprises the photosensitizer or a derivative of the photosensitizer. 7. The MOF of claim 6, wherein at least one bridging ligand comprises a porphyrin, a chlorin, a chlorophyll, a phthalocyanine, a ruthenium-bipyridine complex, or an iridium-bipyridine complex. 8. The MOF of claim 7, wherein at least one bridging ligand is: 9. The MOF of claim 1, wherein at least one bridging ligand is a porphyrin-based ligand, a chlorin-based ligand, a bacteriochlorin-based ligand, a boron-dipyrromethene (BODIPY) derivative or a disalicylidene-1,2-cyclohexylidenediamine derivative. 10. The MOF of claim 9, wherein at least one of the bridging ligands is selected from 5, 15-di(p-benzoato)porphyrin (DBP) or a derivative and/or metal complex thereof; 5, 15-di(p-benzoato)chlorin (DBC) or a derivative and/or metal complex thereof; 5, 15-di(p-benzoato)bacteriochlorin (DBBC) or a derivative and/or metal complex thereof; 5, 10, 15, 20-tetra(p-benzoato) porphyrin or a derivative and/or a metal complex thereof; 5, 10, 15, 20-tetra(p-pyridyl)porphyrin, phthalocyanine-octacarboxylic acid, optionally complexed with a metal; a platinum or palladium complex of di(5′-benzoatosalicylidene)-1,2-cyclohexylidenediamine; a phthalocyanine, optionally substituted with a metal; and motexafin lutetium. 11. The MOF of claim 1, wherein at least one of the bridging ligands is selected from the group consisting of Protoporphyrin IX, Padoporfin; tetra(m-hydroxyphenyl)chlorin (m-THPC); NPe6, Chlorin e6, Rostaporfin and derivatives thereof. 12. The MOF of claim 1, wherein the photosensitizer is a covalently attached dye, optionally wherein the dye is covalently attached via an amide or a thiourea bond. 13. The MOF of claim 12, wherein at least one of the bridging ligands is a para-quaterphenyldicarboxylic acid derivative. 14. The MOF of claim 13, wherein the MOF comprises 15. The MOF of claim 1, wherein the photosensitizer is a dye noncovalently trapped within the MOF. 16. The MOF of claim 1, wherein the photosensitizer is a covalently attached dye or a dye noncovalently trapped within the MOF, wherein the dye is a compound or a derivative of a compound selected from the group consisting of toluidine blue, methylene blue, Nile blue, hypericin, Cy3, Cy3.5, Cy5, Cy5.5, Cy7, and a chalcogenopyrylium. 17. The MOF of claim 1, wherein the photosensitizer is selected from the group consisting of Protoporphyrin IX, Padoporfin; tetra(m-hydroxyphenyl) chlorin (m-THPC); NPe6, Chlorin e6, Rostaporfin and derivatives thereof. 18. The MOF of claim 1, further comprising a non-covalently bound platinum-based drug, temozolomide, doxorubicin, camptothecin, paclitaxel, pemetrexed, methotrexate, or an IDO inhibitor, optionally wherein the IDO inhibitor is selected from the group consisting of ICBN24360, NLG-919, 1-methyl-D-tryptophan and 1-methyl-L-tryptophan. 19. The MOF of claim 1, further comprising a polyethylene glycol (PEG) moiety or one or more lipid molecule bound covalently or electrostatically, optionally wherein the one or more lipid molecule is selected from the group comprising 1,2-dioleoyl-3-trimethylammonium propane (DOTAP), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), and a 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)] (DSPE-PEG).